National comprehensive cancer network (NCCN) recommendations for drugs without US food and drug administration (FDA) approval in metastatic breast cancer: A cross-sectional study

被引：0
|
作者：
Etan, Tal [1 ]
Amir, Eitan [2 ]
Tibau, Adriana [3 ]
Yerushalmi, Rinat [4 ]
Moore, Assaf [4 ]
Shepshelovich, Daniel [1 ]
Goldvaser, Hadar [4 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[4] Rabin Med Ctr, Petah Tiqwa, Israel
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS14-13
引用
收藏
页数：1
相关论文
共 50 条
  • [1] National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study
    Etan, Tal
    Amir, Eitan
    Tibau, Adriane
    Yerushalmi, Rinat
    Moore, Assaf
    Shepshelovich, Daniel
    Goldvaser, Hadar
    CANCER TREATMENT REVIEWS, 2020, 91
  • [2] Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study
    Cliff, Edward Robert Scheffer
    Rome, Rachel S.
    Kesselheim, Aaron S.
    Rome, Benjamin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] US Food and Drug Administration Approval Overview in Metastatic Breast Cancer
    Cortazar, Patricia
    Justice, Robert
    Johnson, John
    Sridhara, Rajeshwari
    Keegan, Patricia
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1705 - 1711
  • [4] Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
    Tibau, Ariadna
    Ocana, Alberto
    Anguera, Georgia
    Seruga, Bostjan
    Templeton, Arnoud J.
    Barnadas, Agusti
    Amir, Eitan
    JAMA ONCOLOGY, 2016, 2 (06) : 744 - 750
  • [5] Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
    Kurzrock, R.
    Gurski, L. A.
    Carlson, R. W.
    Ettinger, D. S.
    Horwitz, S. M.
    Kumar, S. K.
    Million, L.
    von Mehren, M.
    Benson, A. B., III
    ANNALS OF ONCOLOGY, 2019, 30 (10) : 1647 - 1652
  • [6] National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
    Cliff, Edward R. Scheffer
    Rome, Rachel S.
    Kesselheim, Aaron S.
    Rome, Benjamin N.
    JAMA NETWORK OPEN, 2023, 6 (11) : E2343285
  • [7] Concordance with National comprehensive cancer network (NCCN) metastatic breast cancer guidelines and impact on overall survival
    Rocque, G. B.
    Williams, C. P.
    Jackson, B. E.
    Halilova, K. I.
    Pisu, M.
    Andres, F.
    Smita, B.
    CANCER RESEARCH, 2017, 77
  • [8] Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
    Iannantuono, G. M.
    Filetti, M.
    Giudice, E.
    Sganga, S.
    Chandran, E. B. A.
    Xue, E.
    Lombardi, P.
    Rosenfeld, R.
    Rapisarda, E.
    Ferri, L.
    De Rubeis, G.
    Lorusso, D.
    Floudas, C.
    Gulley, J. L.
    Apolo, A. B.
    Lee, J-M.
    Karzai, F.
    Altamura, V.
    Scambia, G.
    Daniele, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S956 - S957
  • [9] Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration
    DiMagno, Sarah S. P.
    Glickman, Aaron
    Emanuel, Ezekiel J.
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 922 - 923
  • [10] A US Food and Drug Administration (FDA) pooled analysis of outcomes for bone only metastatic breast cancer (MBC).
    Wedam, Suparna B.
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shenghui
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Kim, Geoffrey
    Kluetz, Paul Gustav
    McKee, Amy E.
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345